ALPEK, S.A.B. de C.V.

DB:27A Stock Report

Market Cap: €1.4b

ALPEK. de Valuation

Is 27A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 27A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 27A (€0.63) is trading above our estimate of fair value (€0.45)

Significantly Below Fair Value: 27A is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 27A?

Key metric: As 27A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 27A. This is calculated by dividing 27A's market cap by their current revenue.
What is 27A's PS Ratio?
PS Ratio0.2x
SalesMex$132.43b
Market CapMex$29.16b

Price to Sales Ratio vs Peers

How does 27A's PS Ratio compare to its peers?

The above table shows the PS ratio for 27A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
SIM0 SIMONA
0.6xn/a€339.0m
FPE3 Fuchs
1.6x3.6%€5.1b
IBU IBU-tec advanced materials
0.7x19.2%€33.3m
LXS LANXESS
0.3x2.8%€2.0b
27A ALPEK. de
0.2x5.6%€29.2b

Price-To-Sales vs Peers: 27A is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does 27A's PS Ratio compare vs other companies in the DE Chemicals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
2HRA H&R GmbH KGaA
0.1x2.7%US$132.33m
NSAK OTI Greentech
0.03xn/aUS$594.62k
B7Y Byotrol
0.04xn/aUS$246.97k
No more companies available in this PS range
27A 0.2xIndustry Avg. 1.0xNo. of Companies4PS00.40.81.21.62+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 27A is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Chemicals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is 27A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

27A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: 27A is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 27A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.63
€0.95
+50.7%
33.4%€1.73€0.51n/a11
Nov ’25€0.58
€0.92
+59.1%
34.2%€1.70€0.51n/a11
Oct ’25€0.56
€0.88
+57.2%
35.9%€1.67€0.50n/a11
Sep ’25€0.56
€0.98
+76.2%
35.1%€1.83€0.55n/a11
Aug ’25€0.59
€0.98
+64.4%
35.1%€1.83€0.55n/a11
Jul ’25€0.66
€0.99
+51.5%
35.5%€1.89€0.56n/a11
Jun ’25€0.76
€1.06
+40.7%
35.7%€2.01€0.60n/a11
May ’25€0.68
€1.06
+56.5%
38.5%€2.02€0.60n/a10
Apr ’25€0.67
€1.12
+67.1%
32.7%€2.04€0.61n/a12
Mar ’25€0.58
€1.15
+98.1%
28.4%€2.01€0.70n/a12
Feb ’25€0.61
€1.25
+104.7%
26.6%€2.00€0.81n/a12
Jan ’25€0.67
€1.20
+80.7%
29.4%€1.98€0.75n/a12
Dec ’24€0.70
€1.22
+73.5%
26.8%€1.97€0.80n/a12
Nov ’24€0.53
€1.22
+130.3%
24.7%€1.93€0.89€0.5812
Oct ’24€0.79
€1.38
+75.8%
22.1%€2.00€1.08€0.5613
Sep ’24€0.90
€1.42
+57.6%
21.7%€2.01€1.09€0.5614
Aug ’24€0.92
€1.48
+61.3%
20.9%€2.00€1.08€0.5914
Jul ’24€0.91
€1.60
+77.2%
15.4%€1.98€1.12€0.6614
Jun ’24€0.92
€1.57
+71.6%
13.5%€1.91€1.09€0.7614
May ’24€0.94
€1.59
+68.5%
10.1%€1.88€1.27€0.6814
Apr ’24€1.02
€1.58
+54.9%
9.9%€1.88€1.27€0.6714
Mar ’24€1.13
€1.71
+51.0%
12.0%€2.23€1.44€0.5814
Feb ’24€1.42
€1.73
+21.8%
10.0%€2.12€1.51€0.6114
Jan ’24€1.31
€1.71
+30.2%
10.1%€2.09€1.50€0.6714
Dec ’23€1.34
€1.80
+34.5%
10.4%€2.21€1.58€0.7015
Nov ’23€1.43
€1.80
+26.1%
10.4%€2.21€1.58€0.5315

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Tokuyama

JP¥196.7b

Produces and sells various chemical products in Japan.

TBT

JP¥16.60

7D

5.7%

1Y

14.5%

Ecora Resources

UK£162.5m

Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.

HGR

UK£0.76

7D

1.5%

1Y

-28.3%

Arkema

€5.7b

Manufactures and sells specialty chemicals and advanced materials worldwide.

V1S

€74.55

7D

-4.4%

1Y

-19.9%